


## Fragile X (FMR1) Carrier Screening and Diagnostic Testing – Update to Ordering Process

### Orderable: Fragile X (FMR1) [LAB1230192]

Beginning February 18<sup>th</sup>, 2025, the Molecular Diagnostics Laboratory will amend the order for Fragile X testing to require an indication for testing – “Prenatal Screening” or “Diagnostic.” The “Prenatal Screening” option should be selected when screening for Fragile X carrier status during pregnancy. The “Diagnostic” option should be selected when there is a diagnostic concern for Fragile X Syndrome (FXS), Fragile X-Associated Ataxia (FXTAS), or Fragile X-Associated Primary Ovarian Insufficiency (FXPOI). These options will be available in the order screen in EPIC and must be selected to complete the order. This change will not impact the assay results; however, result interpretations specific with the order indication will be reported.

Specimen requirements and turnaround time will remain the same.

Order Prior to February 18 <sup>th</sup> , 2025	New Order
Fragile X (FMR1) Carrier Screening and Diagnostic Testing	Fragile X (FMR1)



The screenshot shows the EPIC order entry interface for Fragile X (FMR1). The 'Indication for ordering' section has two tabs: 'Prenatal Screening' and 'Diagnostic'. The 'Release to Patient' section has two options: 'Immediate' and 'Delay - 3 days'. The 'Specimen Type' is set to 'Blood' and the 'Specimen Source' is set to 'Blood, Venous'. The 'Add-on' section shows 'No add-on specimen found'. The 'CC Results' section has two options: 'My List' and 'Other'. The 'Enter recipients' field is empty. The 'Next Required' and 'Link Order' buttons are visible at the bottom left. The 'Accept' and 'Cancel' buttons are visible at the top right and bottom right.

For questions, please contact Pathology Client Services at (804) 828-7284 or the Molecular Diagnostics Laboratory at (804) 828-9564.